1-5 of 5
Ellen J. Schlette
Close
Sort by
Journal Articles

Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors

Clinical Trials & Observations
Paolo Strati, Ellen J. Schlette, Luisa M. Solis Soto, Daniela E. Duenas, Mariela Sivina, Ekaterina Kim, Michael J. Keating, William G. Wierda, Alessandra Ferrajoli, Hagop Kantarjian, Zeev Estrov, Nitin Jain, Philip A. Thompson, Ignacio I. Wistuba, Jan A. Burger
Journal: Blood
Blood (2020) 135 (7): 510–513.
https://doi.org/10.1182/blood.2019003570
Published: 2020
Journal Articles

Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia

Clinical Trials & Observations
Lorenzo Falchi, Michael J. Keating, Edith M. Marom, Mylene T. Truong, Ellen J. Schlette, Rachel L. Sargent, Long Trinh, Xuemei Wang, Susan C. Smith, Nitin Jain, Zeev Estrov, Susan O’Brien, William G. Wierda, Susan Lerner, Alessandra Ferrajoli
Journal: Blood
Blood (2014) 123 (18): 2783–2790.
https://doi.org/10.1182/blood-2013-11-536169
Published: 2014
Journal Articles

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

Clinical Trials & Observations
Alessandra Ferrajoli, Bang-Ning Lee, Ellen J. Schlette, Susan M. O'Brien, Hui Gao, Sijin Wen, William G. Wierda, Zeev Estrov, Stefan Faderl, Evan N. Cohen, Changping Li, James M. Reuben, Michael J. Keating
Journal: Blood
Blood (2008) 111 (11): 5291–5297.
https://doi.org/10.1182/blood-2007-12-130120
Published: 2008
Journal Articles

ZAP70 Expression by Immunohistochemistry Correlates with IgVH Mutation Status in Chronic Lymphocytic Leukemia and Predicts Time to Progression, but Survival Is Decreased in p53-Positive CLL, Regardless of ZAP70 Expression.

Ellen J. Schlette, MD, Constantine Tam, MBBS, Joan Admirand, MD, William Wierda, MD, Susan O’Brien, MD, Susan Lerner, MS, Michael J. Keating, MBBS
Journal: Blood
Blood (2007) 110 (11): 3083.
https://doi.org/10.1182/blood.V110.11.3083.3083
Published: 2007
Journal Articles

Lenalidomide Induces Complete and Partial Responses in Patients with Relapsed and Treatment-Refractory Chronic Lymphocytic Leukemia (CLL).

Alessandra Ferrajoli, MD, Susan M. O’Brien, MD, Stefan H. Faderl, MD, William G. Wierda, MD, PhD, Dietrich Davis, RN, Bang-Ning Lee, PhD, James M. Reuben, PhD, Ellen J. Schlette, MD, Hagop M. Kantarjian, MD, Michael J. Keating, MBBS
Journal: Blood
Blood (2006) 108 (11): 305.
https://doi.org/10.1182/blood.V108.11.305.305
Published: 2006